Skip to content

Search

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression

Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in approximately 10% of acute leukemias and characteristically define disease with poor outcome.

Incidence and survival for childhood central nervous system tumours in Australia, 1983–2016

To investigate incidence and survival of childhood tumours of the central nervous system (CNS) by histological subtype, tumour behaviour and tumour grade. Methods: National, population-based data on all children under 15 years old diagnosed with a CNS tumour between 1983 and 2016 were sourced from the Australian Childhood Cancer Registry. Incidence rate trends were calculated using Joinpoint regression.

Viridans Group Streptococci in Pediatric Leukemia and Stem Cell Transplant: Review of a Risk-stratified Guideline for Empiric Vancomycin in Febrile Neutropenia

Viridans group streptococci (VGS) are an important cause of sepsis in immunosuppressed children. We reviewed the effectiveness of risk-stratified addition of vancomycin to empiric febrile neutropenia therapy among 107 children with leukemia or undergoing an allogeneic transplant.

Six finalists cement The Kids' research excellence in milestone Premier's Science Awards

Six scientists from The Kids Research Institute Australia have been named finalists across four categories in the 2026 Premier's Science Awards.

Biobank funding supports valuable research resources

Four The Kids Research Institute Australia-based biobanks which underpin a range of cancer, respiratory and early life research have received more than $450,000 in funding.

Multi-million-dollar investment in child health to support vital research

Four The Kids Research Institute Australia researchers have received prestigious fellowships and four significant cohort studies led or co-led by The Kids have received key grants under two new funding programs supported by the State Government’s Future Health Research and Innovation (FHRI) Fund.

WA Kids Cancer Centre

The WA Kids Cancer Centre brings together clinicians and researchers working together to defeat childhood cancer.

Why timing matters: How tumours respond to immunotherapy treatments over time

Researchers have identified key differences between cancers that respond to immunotherapy and those that do not.

WA children with most aggressive cancers to benefit from Australian-first personalised medicine clinical trial

Personalised medicine for childhood cancers in West Australia is a step closer thanks to the Zero Childhood Cancer program’s state clinical trial launched today

Bone density treatment found to slow the progression of leukaemia

The Kids Research Institute Australia researchers may have unlocked a vital key to reducing the progression of leukaemia in children, potentially prompting a change in thinking around the best way to target treatment.